Keywords: Gilead Sciences, Financial results, Fourth-quarter and full-year 2012, HIV drug pricing, AHF

Gilead 4th-qtr sales and earnings beat forecasts, but slammed for "greed" by AHF

Article | 05 February 2013

USA-based Gilead Sciences (Nasdaq: GILD), the leading maker of HIV/AIDS drugs, yesterday posted financial results, showing that total revenues ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Gilead Sciences

Go to company listing